MACKinactive

MERRIMACK PHARMACEUTICALS INC

Healthcare·Oncology·Commercial
OncologyNeurologyImmunology

MERRIMACK PHARMACEUTICALS INC (MACK): 4 pipeline candidates · ~3235 mo cash runway · 1 clinical trial. Updated within the last hour.

9.3/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway10.0

3234.6 months

Financial Health9.8

D/E 0.10 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth7.2

4 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for MERRIMACK PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

$234.2M

Quarterly Burn

$226K

Runway

3234.6 mo

Revenue

—

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jan 2296
Today~3558 mo out
Catalyst within runway

Pipeline (4 candidates)

DrugPhase
mm-111Preclinical
mm-121Phase 2
mm-401Preclinical
onivydeApproved
1 clinical trial

Frequently asked questions

How many drug candidates are in MERRIMACK PHARMACEUTICALS INC's pipeline?

MERRIMACK PHARMACEUTICALS INC (MACK) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is MERRIMACK PHARMACEUTICALS INC's lead drug candidate?

MERRIMACK PHARMACEUTICALS INC's most advanced tracked candidate is mm-111 (Preclinical) for solid tumors of any origin that have an NRG1 fusion.

What is MERRIMACK PHARMACEUTICALS INC's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, MERRIMACK PHARMACEUTICALS INC has approximately 3234.6 months of cash runway.

Get the full picture on MERRIMACK PHARMACEUTICALS INC

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar